Literature DB >> 25446678

Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Xi-Ling Jiang1, Hong-Wu Shen, Ai-Ming Yu.   

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are serotonin (5-HT) analogs often abused together, which alters thermoregulation that may indicate the severity of serotonin toxicity. Our recent studies have revealed that co-administration of monoamine oxidase inhibitor harmaline leads to greater and prolonged exposure to 5-HT agonist 5-MeO-DMT that might be influenced by cytochrome P450 2D6 (CYP2D6) status. This study was to define the effects of harmaline and 5-MeO-DMT on thermoregulation in wild-type and CYP2D6-humanized (Tg-CYP2D6) mice, as well as the involvement of 5-HT receptors. Animal core body temperatures were monitored noninvasively in the home cages after implantation of telemetry transmitters and administration of drugs. Harmaline (5 and 15 mg/kg, i.p.) alone was shown to induce hypothermia that was significantly affected by CYP2D6 status. In contrast, higher doses of 5-MeO-DMT (10 and 20 mg/kg) alone caused hyperthermia. Co-administration of harmaline (2, 5 or 15 mg/kg) remarkably potentiated the hyperthermia elicited by 5-MeO-DMT (2 or 10 mg/kg), which might be influenced by CYP2D6 status at certain dose combination. Interestingly, harmaline-induced hypothermia was only attenuated by 5-HT1A receptor antagonist WAY-100635, whereas 5-MeO-DMT- and harmaline-5-MeO-DMT-induced hyperthermia could be suppressed by either WAY-100635 or 5-HT2A receptor antagonists (MDL-100907 and ketanserin). Moreover, stress-induced hyperthermia under home cage conditions was not affected by WAY-100635 but surprisingly attenuated by MDL-100907 and ketanserin. Our results indicate that co-administration of monoamine oxidase inhibitor largely potentiates 5-MeO-DMT-induced hyperthermia that involves the activation of both 5-HT1A and 5-HT2A receptors. These findings shall provide insights into development of anxiolytic drugs and new strategies to relieve the lethal hyperthermia in serotonin toxicity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25446678      PMCID: PMC4310233          DOI: 10.1016/j.neuropharm.2014.10.013

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  66 in total

Review 1.  Animal models of the serotonin syndrome: a systematic review.

Authors:  Robert Haberzettl; Bettina Bert; Heidrun Fink; Meredith A Fox
Journal:  Behav Brain Res       Date:  2013-09-01       Impact factor: 3.332

2.  Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.

Authors:  J C Winter; D J Amorosi; Kenner C Rice; Kejun Cheng; Ai-Ming Yu
Journal:  Pharmacol Biochem Behav       Date:  2011-05-23       Impact factor: 3.533

3.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

Authors:  Kirsten Krebs-Thomson; Erbert M Ruiz; Virginia Masten; Mahalah Buell; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

4.  Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats.

Authors:  A F Abdel-Fattah; K Matsumoto; Y Murakami; H Adel-Khalek Gammaz; M F Mohamed; H Watanabe
Journal:  Gen Pharmacol       Date:  1997-03

5.  Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Kristopher W Krausz; Adrian Küpfer; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

6.  Cold-activated brown adipose tissue in healthy men.

Authors:  Wouter D van Marken Lichtenbelt; Joost W Vanhommerig; Nanda M Smulders; Jamie M A F L Drossaerts; Gerrit J Kemerink; Nicole D Bouvy; Patrick Schrauwen; G J Jaap Teule
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

7.  JL13 has clozapine-like actions on thermoregulatory cutaneous blood flow in rats: Involvement of serotonin 5-HT1A and 5-HT2A receptor mechanisms.

Authors:  B Capuano; I T Crosby; F M McRobb; D A Taylor; A Vom; W W Blessing
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-10-29       Impact factor: 5.067

Review 8.  Brown adipose tissue in adult humans: a metabolic renaissance.

Authors:  Paul Lee; Michael M Swarbrick; Ken K Y Ho
Journal:  Endocr Rev       Date:  2013-04-02       Impact factor: 19.871

Review 9.  Recognizing serotonin toxicity in the pediatric emergency department.

Authors:  Shruti Kant; Erica Liebelt
Journal:  Pediatr Emerg Care       Date:  2012-08       Impact factor: 1.454

10.  Ability of ketanserin to block different receptors in human placental vessels.

Authors:  J Marin; J Reviriego; M S Fernandez-Alfonso
Journal:  J Pharm Pharmacol       Date:  1990-03       Impact factor: 3.765

View more
  7 in total

1.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

2.  Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Stephan Schmidt; Ai-Ming Yu
Journal:  Acta Pharm Sin B       Date:  2016-08-06       Impact factor: 11.413

3.  Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish.

Authors:  Robson Savoldi; Daniel Polari; Jaquelinne Pinheiro-da-Silva; Priscila F Silva; Bruno Lobao-Soares; Mauricio Yonamine; Fulvio A M Freire; Ana C Luchiari
Journal:  Front Behav Neurosci       Date:  2017-07-28       Impact factor: 3.558

4.  It's Tea Time: Interference of Ayahuasca Brew on Discriminative Learning in Zebrafish.

Authors:  Bruno Lobao-Soares; Paulianny Eduardo-da-Silva; Hugo Amarilha; Jaquelinne Pinheiro-da-Silva; Priscila F Silva; Ana Carolina Luchiari
Journal:  Front Behav Neurosci       Date:  2018-08-27       Impact factor: 3.558

Review 5.  A narrative synthesis of research with 5-MeO-DMT.

Authors:  Anna O Ermakova; Fiona Dunbar; James Rucker; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2021-10-19       Impact factor: 4.153

Review 6.  The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

Authors:  Johannes T Reckweg; Malin V Uthaug; Attila Szabo; Alan K Davis; Rafael Lancelotta; Natasha L Mason; Johannes G Ramaekers
Journal:  J Neurochem       Date:  2022-03-08       Impact factor: 5.546

7.  Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.

Authors:  Marlaina R Stocco; Cole Tolledo; Fariba Baghai Wadji; Frank J Gonzalez; Sharon Miksys; Rachel F Tyndale
Journal:  Mol Neurobiol       Date:  2020-08-06       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.